| Literature DB >> 36158796 |
Jiaqi Hui1,2,3, Ya Wang1,2,3, Junnan Zhao2,3, Weihong Cong1,3, Fengqin Xu2,3.
Abstract
Background: Chronic heart failure (CHF) is among the top causes of cardiovascular morbidity, and most patients with CHF have poor health status. Tai Chi, a mind-body exercise that originated in China, is beneficial for health status. This study was conducted to evaluate the effects of Tai Chi on health status in adults with CHF.Entities:
Keywords: Tai Chi; chronic heart failure; health status; meta-analysis; systematic review
Year: 2022 PMID: 36158796 PMCID: PMC9500215 DOI: 10.3389/fcvm.2022.953657
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
FIGURE 1Flow diagram of the study selection process. CHF, chronic heart failure; CNKI, China National Knowledge Infrastructure; RCT, randomized controlled trial; SinoMed, Chinese Biomedical Database; VIP, Chinese Scientific Journal Database (Chinese VIP Information).
Characteristics of the 15 trials included in the systematic review and meta-analysis.
| References | Country | Age (mean ± SD, year) | Gender (male/female) | Sample size (Tai Chi/Control) | Participants | NYHA | LVEF (mean ± SD, %) | Intervention: Tai Chi group | Control group | Outcomes | |||
| Form/Style | Frequency | Duration (month) | Total exercise time per week | ||||||||||
| Caminiti et al. ( | Italy | >65 (73.8 ± 6) | 51/9 | 60 (30/30) | CHF due to left ventricular systolic dysfunction | II | <45 (33 ± 9) | A modified 10-movement Yang style (10 min of warm-up exercises, 30 min of Tai Chi practice, and 10 min of cool-down exercises) | 1 h/time, 4 times/week | 3 | 240 min | Endurance training (10 min of warm-up, 10 min of cool-down and flexibility exercises, and 30 min of aerobic exercise with cycling or walking at 60–70% of estimated VO2 max) | 6MWT, NT-pro-BNP |
| Ding and Chen ( | China | 50–69 (61.4 ± 5.2) | 19/11 | 60 (30/30) | CHF | II or III | Not report | Chen-style of Tai Chi, usual care: Qili qiangxin capsules (4 pills, t.i.d., p.o.), acupressure, and dietary. | 30 min/session, 2 sessions/day, 7 days/week | 3 | 420 min | Usual care: Qili qiangxin capsules (4 pills, t.i.d., p.o.), acupressure, and dietary. | MLHFQ, 6MWT |
| Liu ( | China | 35–65 (54.98 ± 7.45) | 31/35 | 66 (33/33) | CHF, CHD | II or III | 44.91 ± 0.59 | Simplified 24 forms of Tai Chi, pharmacologic therapy (diuretics, vasodilators, angiotensin-converting enzyme inhibitors, beta-blockers, etc.) | 1 h/time, 3–4 times/week | 3 | 240 min | Pharmacologic therapy (diuretics, vasodilators, angiotensin-converting enzyme inhibitors, beta-blockers, etc.) | MLHFQ, 6MWT, LVEF |
| Pan ( | China | 61–82 (66.96 ± 11.88) | 35/26 | 61 (31/30) | CHF | II or III | ≤45 (32.74 ± 7.25) | Simplified 24 forms of Tai Chi, usual care: dietary, health education, pharmacologic therapy (diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, etc.) | ≥30 min/day, 7 days/week | 6 | 210 min | Usual care: dietary, health education, pharmacologic therapy (diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, etc.) | LVEF, 6MWT, BNP |
| Sang et al. ( | China | 61–80 (70.75 ± 9.55) | 57/43 | 100 (50/50) | CHF, CHD | II or III | 36.7 ± 2.9 | Tai Chi rehabilitation, pharmacologic therapy | 15 min/day, 7 days/week | 3 | 105 min | Pharmacologic therapy | MLHFQ, 6MWT, LVEF |
| Sang et al. ( | China | 60–77 (65.75 ± 5.83) | 35/25 | 60 (30/30) | CHF, CHD | II or III | 35.95 ± 2.89 | Tai Chi rehabilitation, pharmacologic therapy | 15 min/day, 7 days/week | 3 | 105 min | Pharmacologic therapy | LVEF, BNP |
| Wang ( | China | 63–71 (66.86 ± 1.86) | 23/33 | 56 (28/28) | CHF | I, II or III | Not report | Simplified 24 forms of Tai Chi, pharmacologic therapy (angiotensin-converting enzyme inhibitors, beta-blockers, etc.) | 30 min/time, 5 times/week | 3 | 150 min | Walking training, pharmacologic therapy (angiotensin-converting enzyme inhibitors, beta-blockers, etc.) | 6MWT |
| Yang et al. ( | China | >65 (70.65 ± 5.88) | 52/42 | 94 (47/47) | CHF | I, II or III | 51.38 ± 2.95 | Simplified 24 forms of Tai Chi, pharmacologic therapy (diuretics, angiotensin-converting enzyme inhibitors, statins, etc.) | 1 h/time, 6 times/week | 12 | 360 min | Pharmacologic therapy (diuretics, angiotensin-converting enzyme inhibitors, etc.) | 6MWT, TUGT, NT-pro-BNP, LVEF |
| Yao et al. ( | China | 52.07 ± 6.76 | 89/61 | 150 (80/70) | CHF | II | 30.56 ± 9.54 | Chen-style 42 forms of Tai Chi, lifestyle change, dietary, pharmacologic therapy (diuretics, vasodilators, beta-blockers, etc.) | ≥30 min/time, 5 times/week | 6 | 150 min | Lifestyle change, dietary, pharmacologic therapy (diuretics, vasodilators, beta-blockers, etc.) | MLHFQ, 6MWT, LVEF |
| Yeh et al. ( | The United States | 64 ± 13 | 19/11 | 30 (15/15) | CHF | I, II, III or IV | ≤40 (23 ± 7) | The five simplified Tai Chi movements adapted from Master Cheng Man-Ch’ing’s Yang-style short form, usual care: pharmacologic therapy (angiotensin-converting enzyme inhibitor, beta-blocker, loop diuretic, digoxin, spironolactone, etc.), dietary and exercise counseling | 1 h/time, two times/week | 3 | 120 min | Usual care: pharmacologic therapy (angiotensin-converting enzyme inhibitor, beta-blocker, loop diuretic, digoxin, spironolactone, etc.), dietary and exercise counseling | MLHFQ, 6MWT, BNP, peak VO2, all-cause death |
| Yeh et al. ( | The United States | 66 ± 12 | 8/8 | 16 (8/8) | CHF | I, II or III | ≥50 (63.5 ± 8.37) | The five simplified Tai Chi movements adapted from Master Cheng Man-Ch’ing’s Yang-style short form | 1 h/time, two times/week | 3 | 120 min | Aerobic exercise control | MLHFQ, LVEF, BNP, 6MWT, peak VO2, TUGT, adverse events, hospitalizations |
| Yu et al. ( | China | 18–75 (59.5 ± 11.9) | 73/47 | 120 (80/40) | CHF | I, II or III | ≤45 (31.5 ± 8.55) | Yang-style simplified 24 forms of Tai Chi, pharmacologic therapy (angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, beta-blocker, loop diuretic, spironolactone, etc.) | 30/60 min/time, 5 times/week | 6 | 300 min | Health education, walking training (30 min), pharmacologic therapy (angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, beta-blocker, loop diuretic, spironolactone, etc.) | 6MWT, BNP, LVEF |
| Yu et al. ( | China | ≥60 (68 ± 6.1) | 106/94 | 200 (100/100) | CHF after myocardial infarction | II or III | ≥45 (46.45 ± 3.895) | Simplified 24 forms of Tai Chi, health education, pharmacologic therapy (diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, etc.) | 20 min/time, two times a day, 7 days/week | 6 | 280 min | Health education, pharmacologic therapy (diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, etc.) | BNP, LVEF, 6MWT, cardiovascular death, hospitalization, MLHFQ |
| Yuan ( | China | 60–80 (66.9 ± 4.76) | 33/27 | 60 (30/30) | CHF | II or III | ≤40 or ≥50 (42.95 ± 3.42) | Simplified 24 forms of Tai Chi, pharmacologic therapy (diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, etc.) | 15–40 min/time, 3–5 times/week | 3 | 200 min | Pharmacologic therapy (diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, etc.) | BNP, LVEF, 6MWT, HAMD, PSQI, MLHFQ |
| Zhou et al. ( | China | 55–69 (62.1 ± 5.78) | 57/46 | 103 (52/51) | CHF | II or III | ≤45 (41.13 ± 4.99) | 24 forms of Tai Chi, cardiac rehabilitation and exercise training | 15–40 min/time, 5 times/week | 3 | 200 min | Cardiac rehabilitation and exercise training | LVEF, HAMD, PSQI, MLHFQ |
CHD, coronary heart disease; CHF, chronic heart failure; BNP, B-type natriuretic peptide; HAMD, Hamilton Depression Rating Scale; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NT-pro-BNP, N-terminal fragment of pro-BNP; NYHA, New York Heart Association; Peak VO2, peak oxygen uptake; PSQI, Pittsburgh Sleep Quality Index; SD, standard deviations; TUGT, timed up and go test; 6MWT, 6-min walk test.
FIGURE 2Risk of bias summary (A) and bias graph (B).
FIGURE 3Meta-analysis of MLHFQ in the Tai Chi group vs. the control group. CI, confidence interval; IV, inverse variance; SD, standard deviation.
FIGURE 4Meta-analysis of 6MWT in the Tai Chi group vs. the control group. CI, confidence interval; IV, inverse variance; SD, standard deviation.
FIGURE 5Meta-analysis of LVEF in the Tai Chi group vs. the control group. CI, confidence interval; IV, inverse variance; SD, standard deviation.
FIGURE 6Meta-analysis of BNP/NT-pro-BNP in the Tai Chi group vs. the control group. CI, confidence interval; IV, inverse variance; SD, standard deviation.
FIGURE 7Meta-analysis of HAMD in the Tai Chi group vs. the control group. CI, confidence interval; IV, inverse variance; SD, standard deviation.
FIGURE 8Meta-analysis of PSQI in the Tai Chi group vs. the control group. CI, confidence interval; IV, inverse variance; SD, standard deviation.
FIGURE 9Meta-analysis of peak VO2 in the Tai Chi group vs. the control group. CI, confidence interval; IV, inverse variance; SD, standard deviation.
FIGURE 10Meta-analysis of TUGT in the Tai Chi group vs. the control group. CI, confidence interval; IV, inverse variance; SD, standard deviation.
FIGURE 11Meta-analysis of heart failure hospitalization in the Tai Chi group vs. the control group. CI, confidence interval.
FIGURE 12Funnel plots of 6MWT (A) and LVEF (B). MD, mean difference.
The results of publication bias and “trim and fill” test.
| Outcomes | Egger’s test | “Trim and fill” test | |
|
|
| ||
| 6MWT | 1.14 | 0.28 | / |
| LVEF | 2.91 | 0.017 | (MD = 1.87; 95% CI: 1.084 to 2.657; |
CI, confidence interval; LVEF, left ventricular ejection fraction; MD, mean difference; 6MWT, 6-min walk test.
The GRADE evidence profile for Tai Chi in the treatment of patients with CHF.
| Certainty assessment | No. of patients | Effect | Certainty | Importance | ||||||||
| No. of studies | Study | Risk of | Inconsistency | Indirectness | Imprecision | Other considerations | [intervention] | [comparison] | Relative | Absolute | ||
|
| ||||||||||||
| 9 | Randomized trials | Serious | Serious | Not serious | Not serious | None | 395 | 381 | – | MD 8.51 lower | ⊕⊕○○ | IMPORTANT |
|
| ||||||||||||
| 13 | Randomized trials | Serious | Serious | Not serious | Not serious | None | 559 | 505 | – | MD 43.74 higher | ⊕⊕○○ | IMPORTANT |
|
| ||||||||||||
| 11 | Randomized trials | Serious | Serious | Not serious | Not serious | Publication bias strongly suspected | 538 | 483 | – | MD 6.07 higher | ⊕○○○ | IMPORTANT |
|
| ||||||||||||
| 9 | Randomized trials | Serious | Serious | Not serious | Not serious | None | 368 | 324 | – | SMD 1.12 lower | ⊕⊕○○ | IMPORTANT |
|
| ||||||||||||
| 2 | Randomized trials | Serious | Serious | Not serious | Not serious | None | 82 | 81 | – | MD 2.89 lower | ⊕⊕○○ | IMPORTANT |
|
| ||||||||||||
| 2 | Randomized trials | Serious | Serious | Not serious | Not serious | None | 82 | 81 | – | MD 2.25 lower | ⊕⊕○○ | IMPORTANT |
|
| ||||||||||||
| 2 | Randomized trials | Serious | Not serious | Not serious | Serious | None | 23 | 23 | – | MD 1.38 higher | ⊕⊕○○ | IMPORTANT |
|
| ||||||||||||
| 2 | Randomized trials | Serious | Not serious | Not serious | Not serious | None | 55 | 55 | – | MD 1.34 lower | ⊕⊕⊕○ | IMPORTANT |
|
| ||||||||||||
| 3 | Randomized trials | Serious | Not serious | Not serious | Not serious | None | 12/120 (10.0%) | 25/117 (21.4%) | RR 0.47 | 113 fewer per 1,000 | ⊕⊕⊕○ | IMPORTANT |
aThe quality of majority of trials were not high. bUnexplained heterogeneity. cThe small size or the combined effect size passing the invalid line. dFunnel plots not completed due to<10 studies in the meta-analysis. BNP, B-type natriuretic peptide; CI, confidence interval; HAMD, Hamilton Depression Rating Scale; LVEF, left ventricular ejection fraction; MD, mean difference; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NT-pro-BNP, N-terminal fragment of pro-BNP; Peak VO2, peak oxygen uptake; PSQI, Pittsburgh Sleep Quality Index; RR, risk ratio; SMD, standardized mean difference; TUGT, timed up and go test; 6MWT, 6-min walk test.